Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma
Status:
Recruiting
Trial end date:
2025-12-25
Target enrollment:
Participant gender:
Summary
This is a prospective single arm, multi-center, phase II clinical trial to observe the
efficacy and safety of zanubrutinib combined with standard chemotherapy in the treatment for
patients with diffuse large B cell lymphoma and CD79A/CD79B genetic abnormality.